natgillin/translations-raw huggingface dataset:
Synagis powder in a clear, colourless, type I glass 10ml vial with bromobutyl rubber stopper and aluminium flip-off seal containing 100 mg palivizumab, providing 100 mg/ ml of palivizumab when reconstituted as recommended.
Prašek Synagis v 10 ml viali iz prozornega, brezbarvnega stekla tipa I z gumijastim zamaškom iz bromobutila in aluminijasto pretržno zaporko vsebuje 100 mg palivizumaba; koncentracija po navodilu pripravljene raztopine je 100 mg/ ml.
Water for injections in a clear, colourless type I glass ampoule containing 1 ml of water for injections
Voda za injekcije v ampuli iz prozornega, brezbarvnega stekla tipa I, ki vsebuje 1 ml vode za injekcije.
SLOWLY add 1.0 ml of water for injections along the inside wall of the vial to minimise foaming.
POČASI dodajte 1, 0 ml vode za injekcije, in sicer vzdolž notranje stene viale, da boste čim bolj omejili penjenje.
Abbott Laboratories Limited Queenborough, Kent ME11 5EL United Kingdom
Abbott Laboratories Limited Queenborough Kent ME11 5EL Velika Britanija
KG D-88397 Biberach an der Riss Germany
KG D- 88397 Biberach an der Riss Nemčija
Abbott SRL I 104010 Campoverdi di Aprilia (Latina) Italy
Abbott SRL I 104010 Campoverdi di Aprilia (Latina) Italija
SYNAGIS 50 mg Outer Carton
SYNAGIS 50 mg – zunanja ovojnina
SYNAGIS 50 mg powder and solvent for solution for injection Palivizumab
Synagis 50 mg prašek in vehikel za raztopino za injiciranje palivizumab
Each vial contains 50 mg palivizumab, providing 100 mg/ ml of palivizumab when reconstituted as recommended.
Vsaka viala vsebuje 50 mg palivizumaba; koncentracija po navodilu pripravljene raztopine je 100 mg/ ml.
Powder and solvent for solution for injection Contents:
Prašek in vehikel za raztopino za injiciranje
1 Vial SYNAGIS 50 mg 1 ampoule 1 ml Water for Injections
1 viala s 50 mg SYNAGISA 1 ampula z 1 ml vode za injekcije
Reconstitute SLOWLY with 0.6 ml Water for Injections.
POČASI pripravite z 0, 6 ml vode za injekcije.
DO NOT SHAKE.
NE PRETRESAJTE!
KEEP OUT OF THE REACH AND SIGHT OF CHILDREN
ZDRAVILO SHRANJUJTE NEDOSEGLJIVO OTROKOM!
SYNAGIS 50 mg Vial Label
SYNAGIS 50 mg – nalepka na viali
SYNAGIS 50 mg powder for solution for injection Palivizumab Intramuscular use
Synagis 50 mg prašek za raztopino za injiciranje palivizumab intramuskularna uporaba
SYNAGIS 100 mg Outer Carton
SYNAGIS 100 mg – zunanja ovojnina
SYNAGIS 100 mg powder and solvent for solution for injection Palivizumab
Synagis 100 mg prašek in vehikel za raztopino za injiciranje palivizumab
100 mg palivizumab, providing 100 mg/ ml of palivizumab when reconstituted as recommended.
100 mg palivizumaba; koncentracija po navodilu pripravljene raztopine je 100 mg/ ml.
Also contains: histidine, glycine and mannitol.
Vsebuje tudi: histidin, glicin, manitol.
1 Vial SYNAGIS 100 mg 1 ampoule 1 ml Water for Injections
1 viala s 100 mg SYNAGISA 1 ampula z 1 ml vode za injekcije
Reconstitute SLOWLY with 1.0 ml Water for Injections.
POČASI pripravite z 1, 0 ml vode za injekcije.
Store in the original container
Shranjujte v originalnem vsebniku.
SYNAGIS 100 mg Vial Label
SYNAGIS 100 mg – nalepka na viali
SYNAGIS 100 mg powder for solution for injection Palivizumab Intramuscular
Synagis 100 mg prašek za raztopino za injiciranje palivizumab intramuskularna uporaba
SYNAGIS Water for injections Ampoule Label Text
SYNAGIS voda za injekcije – besedilo nalepke na viali
Read all of this leaflet carefully because it contains important information for you and your child.
Pred uporabo natančno preberite navodilo, ker vsebuje za vas in vašega otroka pomembne podatke.
You may need to read it again. − If you have any further questions, ask your doctor or pharmacist. − This medicine has been prescribed for your child.
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali s farmacevtom.
Do not pass it on to others.
Njim bi lahko cello
It may harm them, even if their symptoms are the same as those of your child. − If any of the side effects get serious, or if you notice that your child has any side effects not listed in this leaflet, please tell your doctor or pharmacist.
učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
What Synagis is and what it is used for 2.
Kaj je zdravilo Synagis in za kaj ga uporabljamo 2.
Before Synagis is given to your child 3.
Kaj morate vedeti, preden bo vaš otrok dobil zdravilo Synagis 3.
How will my child receive Synagis 4.
Kako bo otrok dobival zdravilo Synagis 4.
How to store Synagis 6.
Shranjevanje zdravila Synagis 6.
WHAT SYNAGIS IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO SYNAGIS IN ZA KAJ GA UPORABLJAMO
Synagis is a medicine to help protect your child from getting severe RSV illness.
Synagis je zdravilo, ki otroka pomaga zaščititi pred hudo obliko bolezni RSV.
BEFORE SYNAGIS IS GIVEN TO YOUR CHILD
KAJ MORATE VEDETI, PREDEN BO VAŠ OTROK DOBIL ZDRAVILO SYNAGIS
Your child should not be given Synagis:
Otrok ne sme dobiti zdravila Synagis:
− if he/ she has ever had an allergic (hypersensitive) reaction to the active ingredient of Synagis (palivizumab) or to any of the other ingredients of Synagis (see a full list of ingredients in Section 6)
Synagis (palivizumab) ali katero od pomožnih snovi v zdravilu Synagis (glejte celoten seznam pomožnih snovi v poglavju 6).
Take special care with Synagis:
Bodite posebno pozorni pri uporabi zdravila Synagis:
− if your child is unwell.
- če otrok ni povsem zdrav.
Please tell your doctor if your child is unwell, as the use of Synagis may need to be delayed. − if your child has any bleeding disorders as Synagis is usually injected into the thigh.
- če ima otrok kakšne krvavitvene motnje, kajti zdravilo Synagis se ponavadi injicira v stegno.
Synagis is not known to interact with other medicines, however, you should inform your doctor of all medicines your child is currently taking before starting Synagis.
Ni znano, da bi imelo zdravilo Synagis medsebojne učinke z drugimi zdravili, vendar morate zdravniku pred začetkom uporabe zdravila Synagis povedati za vsa zdravila, ki jih vaš otrok trenutno dobiva.
HOW WILL MY CHILD RECEIVE SYNAGIS
KAKO BO OTROK DOBIVAL ZDRAVILO SYNAGIS
Synagis should be given to your child at a dose of 15 mg/ kg body weight once a month for as long as the risk of RSV infection remains.
Otrok mora zdravilo Synagis dobivati v odmerku 15 mg/ kg telesne mase enkrat na mesec, dokler obstaja tveganje za okužbo z RSV.
For your child’ s best protection, it is necessary to take the doctor’ s advice about when to return for additional doses of Synagis.
Za najboljšo zaščito vašega otroka upoštevajte zdravnikova navodila o tem, kdaj je treba priti po dodatne odmerke zdravila Synagis.
What should you do if you feel that your child has become ill while being treated with Synagis?
Kaj storiti, če se vam zdi, da je otrok v obdobju, ko se zdravi z zdravilom Synagis, zbolel?
If your child becomes ill, please contact your doctor immediately.
Če otrok zboli, se takoj obrnite na zdravnika.
If you have any further questions on how this product will be given to your child, ask your doctor or pharmacist.
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali s farmacevtom.
Like all medicines, Synagis can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Synagis neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
What side effects may occur while taking Synagis?
Kakšni neželeni učinki se lahko pojavijo med uporabo zdravila Synagis?
Common (affects 1 to 10 users in 100): fever; nervousness; redness or swelling at the injection site; diarrhoea.
Pogosti (pojavijo se pri 1 do 10 bolnikih od 100 bolnikov): zvišana telesna temperatura; živčnost; pordelost ali oteklina na mestu injiciranja; driska.
Uncommon (affects 1 to 10 users on 1000): colds coughs runny nose wheeze, vomiting rash pain; viral infection; bleeding; weakness; constipation; drowsiness; hyperactivity; decrease in white blood cell counts; increase in liver function tests which will be seen in blood tests.
Občasni (pojavijo se pri 1 do 10 bolnikih od 1. 000 bolnikov): prehlad; kašelj; smrkanje; piskajoče dihanje; bruhanje; izpuščaj; bolečine; virusne okužbe; krvavitev; šibkost; zaprtje; omotica; hiperaktivnost; zmanjšanje števila belih krvnih celic; zvišanje testov jetrne funkcije, kar bo razvidno iz krvnih testov.
29 Rare (affects 1 to 10 users in 10,000):
29 Redki (pojavijo se pri 1 do 10 bolnikih od 10. 000 bolnikov): premor v dihanju ali druge težave z dihanjem.
Very rare (affects less than 1 user in 10,000); severe allergic reactions.
Zelo redki (pojavijo se pri manj kot 1 bolniku od 10. 000 bolnikov): hude alergijske reakcije.
What should you do if side effects occur?
Kaj morate storiti, če se pojavijo neželeni učinki?
If your child shows any side effects after receiving Synagis you should contact your doctor.
Če se otroku potem, ko je dobil zdravilo Synagis, pojavijo kakršnikoli neželeni učinki, se obrnite na zdravnika.
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, contact your doctor.
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
HOW TO STORE SYNAGIS
SHRANJEVANJE ZDRAVILA SYNAGIS
Do not use Synagis after the expiry date which is stated on the label.
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini.
Store in a refrigerator (2ºC-8°C) until used.
Dokler zdravilo Synagis ni uporabljeno, ga je treba shranjevati v hladilniku (2°C - 8°C).
- Each vial contains 50 mg palivizumab, providing 100 mg/ ml of palivizumab when reconstituted
- Vsaka viala vsebuje 50 mg palivizumaba; koncentracija po navodilu pripravljene raztopine je
as recommended.
100 mg/ ml.
- The other ingredients are histidine, glycine and mannitol.
- Pomožne snovi so histidin, glicin in manitol.
What Synagis looks like and contents of the pack Synagis is a white to off-white uniform dry cake in a 4 ml vial.
Zdravilo Synagis je bel do sivo bel suh prašek z enakomernimi delci v 4 ml viali.
This cake is reconstituted with the Water for Injections before being injected.
Raztopino se pred injiciranjem pripravi z vodo za injekcije.
Abbott Laboratories, Limited Queenborough Kent ME11 5EL United Kingdom
Abbott Laboratories, Limited Queenborough Kent ME11 5EL Velika Britanija
AbbottSRL I 04011 Campoverde di Aprilia, (Latina) Italy
Abbott SRL I 0401 1 Campoverde di Aprilia, (Latina) Italija
Λεωφόρος Βουλιαγμένης 512 GR 174 56 Άλιμος, Αθήνα Τηλ: +30 21 0 9985-222
Postępu 18A Λεωφόρος Βουλιαγμένης 512 PL - 02- 676 Warszawa GR 174 56 Άλιμος, Αθήνα Τηλ: + 30 21 0 9985- 222
Estrada de Alfragide, nº 67 Alfrapark, Edifício D, 2610-008 Amadora Tel: + 351 (0) 21 472 7100
Estrada de Alfragide, nº 67 Alfrapark, Edifício, 2610- 008 Amadora Portugal Tel: + 351 (0) 21 472 7100
Ísland Vistor hf.
Ísland PharmaNor hf.
Karadž ič ova 10 SK-821 08 Bratislava 2 Tel: + 421 (0) 2 4445 4176
Karadžičova 10 SK- 821 08Bratislava 2 Tel: + 421 (0) 2 4445 4176
32 --------------------[perforation to separate from patient information]------------------
32 -------------------- [perforacija za odtrganje od navodila za bolnika] ------------------
ADMINISTRATOR’ S INSTRUCTIONS
NAVODILO ZA ZDRAVSTVENO OSEBJE
DO NOT SHAKE VIAL.
VIALE NE STRESAJTE!
When reconstituted as recommended the final concentration is 100 mg/ ml.
Če je raztopina pripravljena po navodilu, je končna koncentracija 100 mg/ ml.
Palivizumab dose per month (ml) = patient weight (kg) x dose (15 mg/ kg) 100 mg/ ml palivizumab
Odmerek palivizumaba na mesec (ml) = bolnikova masa (kg) x odmerek (15 mg/ kg) 100 mg/ ml palivizumaba
For example, for a baby with a bodyweight of 3 kg, the calculation becomes:
Tako je npr. izračun za dojenčka s telesno maso 3 kg:
3 x 15 = 0.45 ml palivizumab dose per month.
3 x 15 = 0, 45 ml palivizumaba na mesec.
Synagis 100 mg powder and solvent for solution for injection Palivizumab
Synagis 100 mg prašek in vehikel za raztopino za injiciranje palivizumab
You may need to read it again. − If you have any further questions, ask your doctor or your pharmacist. − This medicine has been prescribed for your child.
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali s farmacevtom.
How will my child receive Synagis 6.
Kako bo otrok dobival zdravilo Synagis 4.
BEFORE SYNAGIS IS GIVEN TO YOUR CHILD
KAJ MORATE VEDETI, PREDEN BO VAŠ OTROK DOBIL ZDRAVILO SYNAGIS?
Common (affects 1 to 10 users in 100):
Kakšni neželeni učinki se lahko pojavijo med uporabo zdravila Synagis?
Uncommon (affects 1 to 10 users in 1000):
Pogosti (pojavijo se pri 1 do 10 bolnikih od 100 bolnikov): zvišana telesna temperatura; živčnost; pordelost ali oteklina na mestu injiciranja; driska.
colds; coughs; runny nose; wheeze; vomiting; rash; pain; viral infection; bleeding; weakness; constipation; drowsiness; hyperactivity; decrease in white blood cell counts; increase in liver function tests which will be seen in blood tests.
Občasni (pojavijo se pri 1 do 10 bolnikih od 1. 000 bolnikov): prehlad; kašelj; smrkanje; piskajoče dihanje; bruhanje; izpuščaj; bolečine; virusne okužbe; krvavitev; šibkost; zaprtje; omotica; hiperaktivnost; zmanjšanje števila belih krvnih celic; zvišanje testov jetrne funkcije, kar bo razvidno iz krvnih testov.
Rare (affects 1 to 10 users in 10,000) • a pause in breathing or other breathing difficulties.
35 Redki (pojavijo se pri 1 do 10 bolnikih od 10. 000 bolnikov): premor v dihanju ali druge težave z dihanjem.
Very rare (affects less than 1 user in 10,000) • severe allergic reactions.
Zelo redki (pojavijo se pri manj kot 1 bolniku od 10. 000 bolnikov): hude alergijske reakcije.
HOW TO STORE SYNAGIS Keep out of the reach and sight of children
SHRANJEVANJE ZDRAVILA SYNAGIS
Stored in a refrigerator (2ºC-8°C) until used.
Dokler zdravilo Synagis ni uporabljeno, ga je treba shranjevati v hladilniku (2°C - 8°C).
- Each vial contains 100 mg palivizumab, providing 100 mg/ml of palivizumab when
- Vsaka viala vsebuje 100 mg palivizumaba; koncentracija po navodilu pripravljene raztopine je
reconstituted as recommended.
100 mg/ ml.
What Synagis looks like and contents of the pack Synagis is a white to off-white uniform dry cake in a 10 ml vial.
Zdravilo Synagis je bel do sivo bel suh prašek z enakomernimi delci v 10 ml viali.
Abbott Laboratories Limited, Queenborough, Kent ME11 5EL, United Kingdom
Abbott Laboratories, Limited Queenborough Kent ME11 5EL Velika Britanija Izdelovalec
Abbott SRL, I 04010 Campoverde di Aprilia, (Latina) Italy
Abbott SRL I 0401 1 Campoverde di Aprilia, (Latina) Italija
België/Belgique/Belgien Abbott SA Parc Scientifique Rue du Bosquet, 2 B-1348 Louvain-la-Neuve Tél/Tel: + 32 10 475311
36 België/ Belgique/ Belgien Abbott SA Parc Scientifique Rue du Bosquet, 2 B- 1348 Louvain- la- Neuve Tél/ Tel: + 32 10 475311
Danmark Abbott Laboratories A/S Emdrupvej 28 C DK-2100 København Ø Tlf: + 45 39 77-00-00
Danmark Abbott Laboratories A/ S Emdrupvej 28C 2100 København Ø Tlf: + 45 39 77- 00- 00
Eesti Abbott Laboratories Baltics Vienības 87h LV-1004 Rīga Läti Tel: + 371 67605580
Eesti Abbott Laboratories Baltics Vienības 87 LV- 1004 Rīga Läti Tel: + 371 67605580
Ελλάδα Abbott Laboratories (ΕΛΛΑΣ)Α.Β.Ε.Ε.
Polska Ελλάδα Abbott Laboratories Poland Sp. z o. o.
Polska Abbott Laboratories Poland Sp. z o.o.
Abbott Laboratories (ΕΛΛΑΣ) Α. Β. Ε. Ε. ul.
GR 174 56 Άλιμος, Αθήνα Τηλ: +30 21 0 9985-222
Postępu 18A Λεωφόρος Βουλιαγμένης 512 PL - 02- 676 Warszawa GR 174 56 Άλιμος, Αθήνα Τηλ: + 30 21 0 9985- 222
Postępu 18A PL - 02-676 Warszawa Tel.: + 48 22 606-10-50
Tel.: + 48 22 606- 10- 50
0035121 4727100
Estrada de Alfragide, nº 67 Alfrapark, Edifício, 2610- 008 Amadora Portugal Tel: + 351 (0) 21 472 7100
Karadžičova 10 SK-821 08 Bratislava 2 Tel: + 421 (0) 2 4445 4176
Karadžičova 10 SK- 821 08Bratislava 2 Tel: + 421 (0) 2 4445 4176
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA) http: // www. emea. europa. eu /.
38 --------------------[perforation to separate from patient information]------------------
38 -------------------- [perforacija za odtrganje od navodila za bolnika] ------------------
ADMINISTRATOR’S INSTRUCTIONS
NAVODILO ZA ZDRAVSTVENO OSEBJE
When reconstituted as recommended the final concentration is 100 mg/ml.
Če je raztopina pripravljena po navodilu, je končna koncentracija 100 mg/ ml.
Palivizumab dose per month (ml) = patient weight (kg) x dose (15 mg/kg) 100 mg/ml palivizumab
Odmerek palivizumaba na mesec (ml) = bolnikova masa (kg) x odmerek (15 mg/ kg) 100 mg/ ml palivizumaba
Ref.
London, 14. december 2006 Sklic dok.
International non-proprietary name (INN): fenofibrate/ metformin hydrochloride
Mednarodno nelastniško ime (INN): fenofibrat/ metforminijev klorid
Patients with type 2 diabetes often have dyslipidaemia (abnormal levels of fat in the blood), such as low levels of high-density lipoprotein (HDL or ‘ good’) cholesterol and high levels of triglycerides.
Bolniki s sladkorno boleznijo tipa 2 imajo pogosto dislipidemijo (nenormalne ravni maščobe v krvi), kot na primer nizke ravni lipoproteinskega holesterola visoke gostote (HDL holesterola ali » dobrega « holesterola) in visoke ravni trigliceridov.
Fenofibrate can help to correct blood fat levels by activating a receptor within cells called ‘ peroxisome proliferator activated receptor (PPAR) alpha’.
Fenofibrat lahko pomaga izravnati ravni maščobe v krvi, tako da aktivira receptor v celicah, imenovan » peroksisomski proliferator aktivirajočega receptorja (PPAR) alfa «.
It examined the effect of adding fenofibrate to the patients ’
Preučevali so učinek dodajanja fenofibrata
(44-20) 74 18 84 00 Fax (44-20) 75 23 71 29 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged existing treatment.
(44- 20) 74 18 84 00 Fax (44- 20) 75 23 71 29 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged k obstoječemu zdravljenju bolnikov.
Following the CHMP’ s opinion, it usually takes around 2 months for the European Commission to grant a licence.
Ko CHMP izda mnenje, Evropska komisija v približno 2 mesecih izda dovoljenje.
If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Če potrebujete več informacij o vašem zdravstvenem stanju ali zdravljenju, preberite navodilo za uporabo (ki so prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
TachoSil is a sponge that is coated with the active substances human fibrinogen and human thrombin.
Zdravilo TachoSil je gobica, obložena z zdravilnima učinkovinama humani fibrinogen in humani trombin.
TachoSil is used during an operation to stop bleeding and to seal the surfaces of internal organs.
Zdravilo TachoSil se uporablja pri operacijah za zaustavitev krvavitve in za zapiranje površin notranjih organov.
TachoSil also acts as a support to stitching during surgery on the blood vessels.
Zdravilo TachoSil prav tako deluje kot pomoč pri šivanju pri operacijah ožilja.
TachoSil is used in adults, when standard techniques are not sufficient.
Zdravilo TachoSil se uporablja pri odraslih, ko standardne tehnike ne zadoščajo.
TachoSil should only be used by an experienced surgeon under sterile conditions.
Zdravilo TachoSil lahko uporablja le izkušen kirurg v sterilnih pogojih.
TachoSil should only be applied directly onto the treatment site.
Zdravilo TachoSil se uporablja le neposredno na mestu zdravljenja.
The sponge should be applied so that it covers 1 to 2 cm beyond the edge of the wound.
Gobica se položi tako, da sega 1– 2 cm preko robov rane.
The number of TachoSil sponges used depends on the size of the wound.
Število uporabljenih gobic TachoSil je odvisno od velikosti rane..
In studies, one to three sponges were usually used (9.5 × 4.8 cm), although up to seven sponges were used in some cases.
V študijah so bile običajno uporabljene 1 do 3 gobice (9, 5 x 4, 8 cm), čeprav so v posameznih primerih uporabili tudi do 7 gobic.
For smaller wounds, the smaller sponges are recommended (4.8 × 4.8 cm or 3.0 × 2.5 cm).
Za manjše rane se priporoča uporaba manjših gobic (4, 8 x 4, 8 cm ali 3, 0 x 2, 5 cm).
Sponges can be cut to size if needed.
Če je treba, se lahko gobica obreže na primerno velikost.
TachoSil must not be applied inside a blood vessel.
Zdravilo TachoSil se ne sme uporabljati znotraj krvnih žil.
TachoSil consists of a sponge made out of collagen, with fibrinogen and thrombin as a dried coating on one surface.
Zdravilo TachoSil sestavlja iz kolagena narejena gobica, ki ima na eni površini posušeno oblogo fibrinogena in trombina.
Thrombin and fibrinogen are natural substances that are obtained from human blood.
Trombin in fibrinogen sta naravni snovi, pridobljeni iz človeške krvi.
On contact with fluid such as blood, the coating on the sponge that contains the active substances dissolves.
Ko pride gobica v stik s tekočino, kot je kri, se obloga na površini gobice, ki vsebuje zdravilni učinkovini, raztopi.
This activates the fibrinogen and thrombin, causing the fibrinogen to be converted into the protein fibrin.
To aktivira fibrinogen in trombin, zaradi česar se fibrinogen pretvori v beljakovino fibrin.
This forms a clot that holds the collagen sponge tightly to the wound surface, preventing bleeding and sealing the tissue.
Tvori se strdek, ki kolagensko gobico tesno poveže s površino rane, kar preprečuje krvavenje in zapira tkivo.
The sponge is left in the body, where it dissolves and disappears completely.
Gobica ostane v telesu, kjer se popolnoma raztopi in izgine.
TachoSil has been studied in six studies.  Two of the studies looked at the effects of TachoSil in stopping bleeding.
Zdravilo TachoSil so proučevali v šestih študijah:  v dveh študijah so raziskovali vpliv zdravila TachoSil na zaustavitev krvavitve.
The main measure of effectiveness was the 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
V študijah pri 240 bolnikih, ki so imeli operacijo na jetrih, so primerjali vpliv zdravila TachoSil in argonskega plazemskega koagulatorja (naprave, s katero termično koaguliramo porezano površino in 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Reproduction is authorised provided the source is acknowledged. time until the blood stopped flowing.
Reproduction is authorised provided the source is acknowledged zmanjšamo krvavenje).
A third study compared TachoSil with standard stitching in 185 patients having kidney surgery.  Two studies were carried out to see if TachoSil could be used as a tissue sealant.
V tretji študiji so pri 185 bolnikih, ki so imeli operacijo na ledvicah, zdravilo TachoSil primerjali z običajnim šivanjem.  Izvedeni sta bili dve študiji, da bi preverili, ali bi bilo mogoče zdravilo TachoSil uporabiti za zapiranje tkiva.
The studies compared TachoSil and standard surgical techniques such as stitching and stapling in a total of 490 patients having lung surgery.
V študijah so pri 490 bolnikih, ki so imeli operacijo na pljučih, primerjali zdravilo TachoSil in standardne kirurške tehnike, kot so šivanje in spenjanje.
Effectiveness was measured by looking at whether air leaked from the lungs after surgery.  The final study looked at the effectiveness of TachoSil in surgery on the heart or major blood vessels.
Merilo učinkovitosti je bilo, ali po operaciji iz pljuč uhaja zrak.  V zadnji študiji so merili učinkovitost zdravila TachoSil pri operacijah na srcu in glavnih krvnih žilah.
The study compared TachoSil with standard materials to aid clotting in 120 patients, around three-quarters of whom also had stitches to help stop the bleeding.
V študiji so pri 120 bolnikih, od katerih je imelo približno 75% tudi šive za pomoč pri zaustavitvi krvavitve, primerjali zdravilo TachoSil s standardnimi materiali za pomoč pri strjevanju.